AccueilP8A • SGX
add
Cordlife
Dernière clôture
0,16 $
Plage sur l'année
0,12 $ - 0,46 $
Capitalisation boursière
41,47 M SGD
Volume moyen
24,84 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
SGX
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
(SGD) | juin 2024info | Variation Y/Y |
---|---|---|
Chiffre d'affaires | 4,60 M | -67,54 % |
Charges d'exploitation | 8,59 M | -6,80 % |
Résultat net | -6,18 M | -655,33 % |
Marge bénéficiaire nette | -134,45 | -1 810,56 % |
Bénéfice par action | — | — |
EBITDA | -6,84 M | -615,37 % |
Taux d'imposition effectif | 8,73 % | — |
Bilan
Total des actifs
Total du passif
(SGD) | juin 2024info | Variation Y/Y |
---|---|---|
Trésorerie/Invest. court terme | 59,54 M | -15,89 % |
Total des actifs | 224,31 M | -4,16 % |
Total du passif | 101,27 M | 3,31 % |
Total des capitaux propres | 123,03 M | — |
Actions en circulation | 256,31 M | — |
Ratio cours/valeur comptable | 0,32 | — |
Rentabilité des actifs | -8,79 % | — |
Retour sur capitaux | -15,66 % | — |
Flux de trésorerie
Variation nette en trésorerie
(SGD) | juin 2024info | Variation Y/Y |
---|---|---|
Résultat net | -6,18 M | -655,33 % |
Trésorerie (opérations) | -2,95 M | -192,71 % |
Trésorerie (invest.) | 2,90 M | 258,76 % |
Trésorerie (financement) | -549,50 k | -19,59 % |
Variation nette en trésorerie | -498,00 k | -153,06 % |
Flux de trésorerie dispo. | -4,65 M | -1 473,26 % |
À propos
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam. Wikipedia
CEO
Date de fondation
2 mai 2001
Site Web
Employés
111